Indivior Reaches Patent Infringement Settlement With Par Pharmaceutical Over Suboxone

Indivior PLC (LON: INDV) Indivior announced on 5/15/18 that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics, Inc. (formerly known as Monosol Rx, LLC), entered into a settlement agreement with Par Pharmaceutical Inc., Par Pharmaceutical Companies Inc., Endo International PLC (collectively, "Par") and IntelGenx Technologies Corp., resolving patent litigation related to Suboxone (buprenorphine and naloxone) Sublingual Film.